Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
Aged
Anticoagulants
/ adverse effects
Atrial Fibrillation
/ complications
Epistaxis
/ chemically induced
Factor Xa Inhibitors
/ adverse effects
Female
Humans
Length of Stay
Male
Middle Aged
Phenprocoumon
/ adverse effects
Pyrazoles
/ adverse effects
Pyridones
/ adverse effects
Retrospective Studies
Risk Assessment
/ methods
Rivaroxaban
/ adverse effects
Apixaban
Atrial fibrillation
Epistaxis
Phenprocoumon
Rivaroxaban
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
8
2
2019
medline:
23
7
2019
entrez:
8
2
2019
Statut:
ppublish
Résumé
Patients taking oral anticoagulants (OACs) currently represent one-third of all patients treated for epistaxis and an upward trend is expected. New direct oral anticoagulants (DOACs) have been on the market for approximately 10 years. DOACs are favoured over Vitamin K-Antagonists (VKAs) in the current guidelines. There are barely studies that investigate the impact of DOACs on patients with epistaxis. A retrospective study was performed analysing all patients who had stationary treatment for epistaxis from 01.01.2011 to 01.01.2018 in a tertiary care centre. In a total of 466 patients, 46.1% were on OACs. The main indication was atrial fibrillation (AF, 67.4%).The number of DOACs taken surpassed that of the VKAs during the past 2 years. The length of hospital stay was significantly longer in the phenprocoumon group (3 ± 0.2 days) in comparison to both the rivaroxaban (2.3 ± 0.1) and the apixaban (2.2 ± 0.1) groups (p = 0.005). Posterior epistaxis occurred more frequently in the phenprocoumon group (10.8%) than in the rivaroxaban (0%) and apixaban (0%) groups (p = 0.03). A correlation between CHA
Identifiants
pubmed: 30729376
doi: 10.1007/s11239-019-01824-x
pii: 10.1007/s11239-019-01824-x
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Rivaroxaban
9NDF7JZ4M3
Phenprocoumon
Q08SIO485D
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
384-391Références
Clin Otolaryngol. 2007 Oct;32(5):361-5
pubmed: 17883556
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
J Laryngol Otol. 2011 Jan;125(1):38-42
pubmed: 20843406
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Eur Heart J. 2012 Nov;33(21):2719-47
pubmed: 22922413
J Laryngol Otol. 2013 May;127(5):483-8
pubmed: 23544790
Dtsch Arztebl Int. 2013 Aug;110(31-32):523-4
pubmed: 24069072
Laryngorhinootologie. 2014 Apr;93(4):249-55
pubmed: 24135824
Acta Otorrinolaringol Esp. 2014 Nov-Dec;65(6):346-54
pubmed: 24958185
Circulation. 2015 Aug 25;132(8):624-32
pubmed: 26106009
Eur Heart J. 2015 Dec 7;36(46):3238-49
pubmed: 26163482
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Rhinology. 2016 Dec 1;54(4):292-391
pubmed: 27591836
Otolaryngol Head Neck Surg. 2017 Sep;157(3):424-431
pubmed: 28463569
Clin Otolaryngol. 2018 Feb;43(1):103-108
pubmed: 28510336
J Laryngol Otol. 2017 Dec;131(12):1131-1141
pubmed: 29280693